THE HEALTH CARE COSTS OF LONG-ACTING INSULIN ANALOGS COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES USING A BASAL REGIMEN: A DANISH PERSPECTIVE

被引：0
|
作者：
Gundgaard, J. [1 ]
Christensen, T. [2 ]
Thomsen, T. L. [2 ]
机构：
[1] COWI, Kongens Lyngby, Denmark
[2] Novo Nordisk AS, Virum, Denmark
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72264-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A57 / A57
页数：1
相关论文
共 50 条
  • [21] Long-Acting Insulin Analogs: A Review of "Real-World" Effectiveness in Patients with Type 2 Diabetes
    Pollock, Richard F.
    Erny-Albrecht, Katrina M.
    Kalsekar, Anupama
    Bruhn, David
    Valentine, William J.
    CURRENT DIABETES REVIEWS, 2011, 7 (01) : 61 - 74
  • [22] Reduced Nocturnal Hypoglycemia and Weight Loss With Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Patients With Type 2 Diabetes
    Bergenstal, Richard M.
    Rosenstock, Julio
    Arakaki, Richard F.
    Prince, Melvin J.
    Qu, Yongming
    Sinha, Vikram P.
    Howey, Daniel C.
    Jacober, Scott J.
    DIABETES, 2012, 61 : A90 - A91
  • [23] Reduced Health Care Costs with Automated Basal Insulin Titration in Patients with Type 2 Diabetes
    Sieber, Jochen
    Bajaj, Harpreet S.
    Kottmann, Tanja
    Venn, Karri
    Aronson, Ronnie
    Flacke, Frank
    DIABETES, 2017, 66 : A354 - A354
  • [24] Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
    Davies, M. J.
    Donnelly, R.
    Barnett, A. H.
    Jones, S.
    Nicolay, C.
    Kilcoyne, A.
    DIABETES OBESITY & METABOLISM, 2009, 11 (12): : 1153 - 1162
  • [25] Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update
    Pedersen-Bjergaard, Ulrik
    Fabricius, Therese W.
    Thorsteinsson, Birger
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (16) : 2251 - 2259
  • [26] Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes
    Parkner, T.
    Laursen, T.
    Vestergaard, E. T.
    Hartvig, H.
    Smedegaard, J. S.
    Lauritzen, T.
    Christiansen, J. S.
    DIABETIC MEDICINE, 2008, 25 (05) : 585 - 591
  • [27] Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients
    Alsofiani, Wafa A.
    Alessa, Bandar H.
    Alsabaan, Fahad
    Althemery, Abdullah U.
    Ghith, Aliah M.
    Alfaifi, Abdullah A.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2022, 15 : 733 - 739
  • [28] Efficacy of Rapid-Acting and Long-Acting Insulin Analogs in Japanese Patients with Type 1 Diabetes Mellitus
    Ozaki, Nobuaki
    Nomura, Yoshio
    Wanibe, Harumatsu
    Yamamori, Ikuo
    Oiso, Yutaka
    DIABETES, 2009, 58 : A524 - A524
  • [29] Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial
    Morrow, L. A.
    Hompesch, M.
    Jacober, S. J.
    Choi, S. Leng
    Qu, Y.
    Sinha, V. P.
    DIABETES OBESITY & METABOLISM, 2016, 18 (11): : 1065 - 1071
  • [30] Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes
    Schmid, C.
    Krayenbuhl, P.
    Wiesli, P.
    DIABETOLOGIA, 2009, 52 (12) : 2668 - 2669
12345